ResMed Inc. — Wall Street Analyst Estimates & Price Targets

RMD

NYSEHealthcareMedical - Instruments & SuppliesCIK 0000943819resmed.comAbout RMD

Last close · Oct 16, 2026238.97−3.26 (−1.35%)

Market cap$33.6B

6 firms' latest targets, last 90 days: median $251.00 ($213.00–$300.00), 5% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 6 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-13	Mizuho Securities	$240.00	$220.00	▲ 9%	+2%	+0%
2026-09-15	RBC Capital	$262.00	$234.00	▲ 12%	+17%	+10%
2026-08-31	KeyBanc	$267.00	$255.00	▲ 5%	+11%	+12%
2026-08-19	Rothschild & Co Redburn	$230.00	—	—	+5%	-4%
2026-08-07	Baird	$213.00	$225.00	▼ 5%	+0%	-11%
2026-07-21	UBS	$300.00	$345.00	▼ 13%	+53%	+26%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$4.2B	+18%	$6.09	+15%	est. $4.2B+0%	est. $6.50	5
2024reported	$4.7B	+11%	$6.92	+14%	est. $4.8B-3%	est. $7.57	8
2025reported	$5.1B	+10%	$9.51	+37%	est. $5.1B+0%	est. $9.51	16
2026reported	$5.7B	+10%	$10.43	+10%	est. $5.6B+0%	est. $11.13	14
2027	$5.8B	+3%	$12.10	+9%	$5.8B–$6.0B	$11.77–$12.27	15
2028	$6.2B	+6%	$13.30	+10%	$6.0B–$6.5B	$13.11–$13.67	13
2029	$6.6B	+6%	$14.56	+9%	$6.5B–$6.6B	$13.75–$15.12	5
2030	$7.1B	+7%	$15.62	+7%	$7.0B–$7.2B	$15.38–$16.01	4

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$251.00median target, 5% above the last close

Firms with a target · last 90 days: 6
Lowest – highest target: $213.00 – $300.00
Current grades of 10 firms: positive / neutral / negative: 3 / 7 / 0
Upgrades / downgrades · 12 months: 1 / 3
Consensus revenue growth · next 3 FY: +5% a year

Current grades

each firm's latest · 10 firms

As of	Firm	Grade
2026-09-15	RBC Capital	“Outperform”
2026-08-31	Keybanc	“Overweight”
2026-08-07	Wells Fargo	“Equal Weight”
2026-08-07	Piper Sandler	“Neutral”
2026-07-15	Mizuho	“Outperform”
2026-07-13	Citigroup	“Neutral”
2026-07-10	Jefferies	“Hold”
2026-06-17	Morgan Stanley	“Equal Weight”
2026-01-30	Stifel	“Hold”
2025-12-16	Baird	“Neutral”

Grade changes

last 24 months · 6

Date	Firm	Grade
2026-09-15	RBC Capital	“Sector Perform” → “Outperform” upgrade
2026-07-13	Citigroup	“Buy” → “Neutral” downgrade
2026-06-17	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2025-12-16	Baird	“Outperform” → “Neutral” downgrade
2025-07-16	RBC Capital	“Sector Perform” → “Outperform” upgrade
2025-03-05	Citigroup	“Neutral” → “Buy” upgrade

54 older than 24 months

2024-09-18	Wolfe Research	“Peer Perform” → “Underperform” downgrade
2024-09-04	Needham	“Buy” → “Hold” downgrade
2024-06-25	Oppenheimer	“Outperform” → “Perform” downgrade
2024-06-24	Citigroup	“Buy” → “Neutral” downgrade
2023-10-27	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2023-10-12	RBC Capital	“Outperform” → “Sector Perform” downgrade
2023-09-29	Wolfe Research	“Outperform” → “Peer Perform” downgrade
2023-09-06	Needham	“Hold” → “Buy” upgrade
2023-09-05	UBS	“Buy” → “Neutral” downgrade
2023-08-01	RBC Capital	“Sector Perform” → “Outperform” upgrade
2023-01-17	J.P. Morgan	“Neutral” → “Overweight” upgrade
2022-10-20	Bank of America	“Neutral” → “Buy” upgrade
2022-09-13	RBC Capital	“Sector Perform” → “Outperform” upgrade
2022-09-08	Citigroup	“Neutral” → “Buy” upgrade
2022-08-12	J.P. Morgan	“Overweight” → “Neutral” downgrade
2022-08-12	RBC Capital	“Outperform” → “Sector Perform” downgrade
2022-06-06	RBC Capital	“Sector Perform” → “Outperform” upgrade
2022-01-31	Citigroup	“Neutral” → “Buy” upgrade
2022-01-28	RBC Capital	“Underperform” → “Sector Perform” upgrade
2022-01-24	Bank of America	“Underperform” → “Neutral” upgrade
2022-01-24	J.P. Morgan	“Neutral” → “Overweight” upgrade
2022-01-13	CLSA	“Outperform” → “Buy” revised
2022-01-13	Baird	“Neutral” → “Outperform” upgrade
2021-12-21	Keybanc	“Sector Weight” → “Overweight” upgrade
2021-12-06	Macquarie	“Neutral” → “Outperform” upgrade
2021-08-02	CLSA	“Outperform” → “Sell” downgrade
2021-08-02	Needham	“Buy” → “Hold” downgrade
2021-07-28	Jefferies	“Underperform” → “Hold” upgrade
2021-07-26	J.P. Morgan	“Overweight” → “Neutral” downgrade
2021-06-16	Bank of America	“Neutral” → “Underperform” downgrade
2021-05-21	J.P. Morgan	“Neutral” → “Overweight” upgrade
2021-05-11	Citigroup	“Neutral” → “Buy” upgrade
2021-03-16	Needham	“Hold” → “Buy” upgrade
2020-05-01	Oppenheimer	“Perform” → “Outperform” upgrade
2020-01-31	UBS	“Buy” → “Neutral” downgrade
2019-11-22	KeyBanc	“Sector Weight” → “Equal Weight” revised
2019-07-29	Goldman Sachs	“Neutral” → “Buy” upgrade
2019-07-29	UBS	“Neutral” → “Buy” upgrade
2019-05-06	UBS	“Neutral” → “Buy” upgrade
2019-04-18	J.P. Morgan	“Underweight” → “Neutral” upgrade
2019-03-20	Deutsche Bank	“Hold” → “Buy” upgrade
2019-01-25	J.P. Morgan	“Neutral” → “Underweight” downgrade
2018-12-10	BMO Capital	“Market Perform” → “Outperform” upgrade
2018-04-04	Citigroup	“Buy” → “Neutral” downgrade
2018-01-23	Needham	“Underperform” → “Hold” upgrade
2017-08-02	Credit Suisse	“Outperform” → “Neutral” downgrade
2017-08-02	Bank of America	“Buy” → “Neutral” downgrade
2017-08-02	Citigroup	“Neutral” → “Buy” upgrade
2017-01-24	J.P. Morgan	“Neutral” → “Overweight” upgrade
2016-09-29	Bank of America	“Neutral” → “Buy” upgrade
2016-09-19	J.P. Morgan	“Overweight” → “Neutral” downgrade
2016-08-23	Jefferies	“Hold” → “Underperform” downgrade
2016-06-27	Needham	“Hold” → “Underperform” downgrade
2016-04-28	Macquarie	“Underperform” → “Neutral” upgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.